Gabather AB (publ) (GABA.ST)
SEK 0.4
(-3.61%)
SEK 0.4
(-3.61%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.11 Million SEK | 82.22% |
| 2022 | -6.27 Million SEK | 57.76% |
| 2021 | -14.84 Million SEK | 51.98% |
| 2020 | -30.91 Million SEK | 31.14% |
| 2019 | -44.89 Million SEK | -169.67% |
| 2018 | -16.64 Million SEK | 54.63% |
| 2017 | -36.69 Million SEK | -31.58% |
| 2016 | -27.88 Million SEK | -176.66% |
| 2015 | -10.08 Million SEK | -26.36% |
| 2014 | -7.97 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -2.36 Million SEK | -112.2% |
| 2024 Q2 | -989 Thousand SEK | 58.2% |
| 2023 FY | -1.11 Million SEK | 82.22% |
| 2023 Q3 | -3.17 Million SEK | 43.29% |
| 2023 Q1 | -7.51 Million SEK | -19.75% |
| 2023 Q2 | -5.59 Million SEK | 25.58% |
| 2023 Q4 | -1.11 Million SEK | 64.83% |
| 2022 Q1 | -11.47 Million SEK | 22.73% |
| 2022 Q3 | -7.85 Million SEK | 19.97% |
| 2022 FY | -6.27 Million SEK | 57.76% |
| 2022 Q4 | -6.27 Million SEK | 20.19% |
| 2022 Q2 | -9.82 Million SEK | 14.4% |
| 2021 FY | -14.84 Million SEK | 51.98% |
| 2021 Q2 | -22.36 Million SEK | 18.24% |
| 2021 Q4 | -14.84 Million SEK | 19.04% |
| 2021 Q3 | -18.33 Million SEK | 17.99% |
| 2021 Q1 | -27.35 Million SEK | 11.54% |
| 2020 Q3 | -33.33 Million SEK | 11.77% |
| 2020 FY | -30.91 Million SEK | 31.14% |
| 2020 Q1 | -41.27 Million SEK | 8.08% |
| 2020 Q4 | -30.91 Million SEK | 7.26% |
| 2020 Q2 | -37.78 Million SEK | 8.45% |
| 2019 Q2 | -9.75 Million SEK | 22.06% |
| 2019 Q1 | -12.51 Million SEK | 24.81% |
| 2019 Q4 | -44.89 Million SEK | -739.39% |
| 2019 FY | -44.89 Million SEK | -169.67% |
| 2019 Q3 | -5.34 Million SEK | 45.18% |
| 2018 FY | -16.64 Million SEK | 54.63% |
| 2018 Q2 | -25.94 Million SEK | 18.72% |
| 2018 Q4 | -16.64 Million SEK | 22.32% |
| 2018 Q3 | -21.43 Million SEK | 17.4% |
| 2018 Q1 | -31.92 Million SEK | 13.01% |
| 2017 FY | -36.69 Million SEK | -31.58% |
| 2017 Q1 | -24.36 Million SEK | 12.65% |
| 2017 Q4 | -36.69 Million SEK | -121.58% |
| 2017 Q3 | -16.56 Million SEK | 22.05% |
| 2017 Q2 | -21.24 Million SEK | 12.78% |
| 2016 Q4 | -27.88 Million SEK | 7.28% |
| 2016 Q2 | -33.26 Million SEK | -313.32% |
| 2016 Q1 | -8.04 Million SEK | 20.16% |
| 2016 FY | -27.88 Million SEK | -176.66% |
| 2016 Q3 | -30.07 Million SEK | 9.58% |
| 2015 Q3 | -11.83 Million SEK | 18.75% |
| 2015 FY | -10.08 Million SEK | -26.36% |
| 2015 Q2 | -14.56 Million SEK | -98.2% |
| 2015 Q1 | -7.34 Million SEK | 7.9% |
| 2015 Q4 | -10.08 Million SEK | 14.81% |
| 2014 Q4 | -7.97 Million SEK | 0.0% |
| 2014 FY | -7.97 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AcuCort AB | -19.24 Million SEK | 94.206% |
| AlzeCure Pharma AB (publ) | -29.1 Million SEK | 96.168% |
| BioGaia AB (publ) | -1.53 Billion SEK | 99.927% |
| Enzymatica AB (publ) | 17.73 Million SEK | 106.286% |
| Enorama Pharma AB (publ) | -5.71 Million SEK | 80.497% |
| Klaria Pharma Holding AB (publ.) | 17.68 Million SEK | 106.305% |
| Moberg Pharma AB (publ) | -55.81 Million SEK | 98.002% |
| Nanexa AB (publ) | -61.13 Million SEK | 98.176% |
| Newbury Pharmaceuticals AB (publ) | -15.3 Million SEK | 92.714% |
| ODI Pharma AB | -2.63 Million SEK | 57.732% |
| Orexo AB (publ) | 302.8 Million SEK | 100.368% |
| Probi AB (publ) | -275.85 Million SEK | 99.596% |
| Swedencare AB (publ) | 1.42 Billion SEK | 100.078% |
| Swedish Orphan Biovitrum AB (publ) | 19.58 Billion SEK | 100.006% |
| Toleranzia AB | -17.45 Million SEK | 93.612% |
| Vivesto AB | -1.29 Million SEK | 14.165% |